Travere Therapeutics Inc Stock Price, News & Analysis

Meissa Vaccines has appointed Frank Glavin as its new Chief Executive Officer, bringing over 20 years of biotech experience, including successful transitions from lab to clinic. Martin Moore, Ph.D., cofounder, will serve as Chief Scientific Officer. Under Glavin's leadership, Meissa aims to advance its AttenuBlock platform, focusing on intranasal vaccines for RSV and COVID-19. Current clinical data shows promising results for both vaccine candidates, with Phase 1 studies demonstrating safety and immunogenicity. The company is committed to tackling respiratory viral infections on a global scale.

On June 10, 2022, Travere Therapeutics (NASDAQ: TVTX) awarded inducement equity grants to ten new employees, comprising 48,750 restricted stock units (RSUs). These RSUs, granted outside the 2018 Equity Incentive Plan, will vest over four years with 25% vesting each year, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent, enhancing the company's capabilities in developing therapies for rare diseases.

Travere Therapeutics (NASDAQ: TVTX) will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. A live webcast of the presentation will be accessible via their website, with a replay available for 30 days afterward. The company is dedicated to supporting individuals with rare diseases by developing crucial therapies in collaboration with the rare disease community. Travere aims to provide hope and effective treatment options for patients and families worldwide.

Travere Therapeutics announced key presentations at the 59th ERA Congress showcasing ongoing Phase 3 studies of sparsentan for IgA nephropathy and focal segmental glomerulosclerosis. The PROTECT study involves 404 patients and demonstrated a significant proteinuria reduction of 49.8% with sparsentan versus 15.1% for irbesartan. Meanwhile, the DUPLEX study, with 371 participants, reported a 42% achievement rate of FSGS remission with sparsentan. Both studies are fully enrolled, with topline results expected in 2023.

Travere Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for sparsentan to treat IgA nephropathy (IgAN) and granted it Priority Review, with a PDUFA target action date of November 17, 2022. If approved, sparsentan would be the first non-immunosuppressive treatment for IgAN, addressing a significant unmet need. The NDA is supported by positive interim results from the Phase 3 PROTECT Study, showing a 49.8% reduction in proteinuria after 36 weeks of treatment, with sparsentan well-tolerated among participants.

Travere Therapeutics (NASDAQ: TVTX) announced on May 10, 2022, the grant of inducement restricted stock units (RSUs) to 15 new employees, covering a total of 91,000 shares. This grant was made outside the 2018 Equity Incentive Plan to encourage new hires, aligning with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting each year, contingent on the employees' continued service. This move underscores Travere's commitment to attracting talent as it focuses on developing treatments for rare diseases.

Travere Therapeutics (TVTX) reported its Q1 2022 results, with total revenue of $48.5 million, slightly down from $47.4 million in Q1 2021, due to decreased Thiola sales. R&D expenses increased to $56.6 million, driven by ongoing pivotal studies for sparsentan. The company reported a net loss of $76.0 million ($1.20 per share), compared to a $53.9 million loss in the prior year. The NDA for sparsentan in IgA nephropathy was submitted, with FDA acceptance expected soon. Cash reserves were strong at $603.4 million.

SAN DIEGO, May 3, 2022 (GLOBE NEWSWIRE) - Travere Therapeutics (NASDAQ: TVTX) announced that CEO Eric Dube, Ph.D., will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. PT. A live webcast of the presentation will be available, along with an archived replay accessible for 30 days post-event.

Travere Therapeutics focuses on developing therapies for patients with rare diseases, emphasizing the need for urgent treatment options and collaboration with the rare disease community.

Travere Therapeutics (NASDAQ: TVTX) plans to release its first quarter 2022 financial results on May 5, 2022, following the U.S. market close. A conference call and webcast to discuss these results and provide a business update is scheduled for 4:30 p.m. ET.

Investors can join the call using the provided dial-in numbers, and a replay will be accessible from 7:30 p.m. ET on May 5 until 7:30 p.m. ET on May 12.